Pegasta 6 mg Injection

Pegasta 6 mg Injection contains Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF) that aids in reducing the risk of infection in patients undergoing chemotherapy by preventing neutropenia—a condition where white blood cell counts are low. Pegfilgrastim works by stimulating bone marrow to produce more white blood cells, bolstering immune health and minimizing infection risks during cancer treatment. This medication is typically administered under medical supervision. Uses:

• Prevention of neutropenia and related infections in patients receiving chemotherapy.
• Enhances immune response by boosting white blood cell production.

Side Effects:

• Common side effects may include bone pain, muscle pain, and headache.
• Rare but serious side effects include spleen enlargement or rupture, severe allergic reactions, and acute respiratory distress syndrome. Consult a healthcare provider for any unusual symptoms.

Key Features:

• Contains Pegfilgrastim, a long-acting G-CSF for white blood cell production.
• Reduces infection risk in chemotherapy patients.
• Designed for convenient, single-dose administration.

References:

• Package leaflet: Information for the user Neulasta 6 mg solution for injection pegfilgrastim. [Revised 2021 Jun] [cited 2023 Feb 23]. Available from: Medicines.org.uk
• Patient Information Neulasta ® (nu-las-tah) (pegfilgrastim) injection Single-Dose Prefilled Syringe. (2021). Available at: Amgen
• HIGHLIGHTS OF PRESCRIBING INFORMATION. (2019). Available at: FDA
• Parker, S.D., & Jacobs, T.F. (2020). Pegfilgrastim. PubMed